UBS Group AG Acquires 30,533 Shares of Arvinas, Inc. (NASDAQ:ARVN)

UBS Group AG increased its position in shares of Arvinas, Inc. (NASDAQ:ARVN – Get Rating) by 10.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 327,639 shares of the company’s stock after purchasing an additional 30,533 shares during the quarter. UBS Group AG owned 0.62% of Arvinas worth $11,209,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Nordea Investment Management AB lifted its position in Arvinas by 816.5% during the fourth quarter. Nordea Investment Management AB now owns 273,955 shares of the company’s stock worth $9,523,000 after purchasing an additional 244,065 shares during the period. Swiss National Bank lifted its holdings in shares of Arvinas by 1.9% in the fourth quarter. Swiss National Bank now owns 109,200 shares of the company’s stock worth $3,736,000 after acquiring an additional 2,000 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Arvinas by 3.9% in the fourth quarter. Arizona State Retirement System now owns 12,761 shares of the company’s stock worth $437,000 after acquiring an additional 480 shares during the last quarter. Handelsbanken Fonder AB bought a new position in shares of Arvinas in the fourth quarter worth about $216,000. Finally, New England Capital Financial Advisors LLC bought a new position in shares of Arvinas in the fourth quarter worth about $34,000. Institutional investors own 92.03% of the company’s stock.

Arvinas Stock Up 8.7 %

NASDAQ:ARVN opened at $24.14 on Tuesday. The company has a fifty day moving average of $26.50 and a 200-day moving average of $32.68. The firm has a market capitalization of $1.29 billion, a P/E ratio of -4.27 and a beta of 1.75. Arvinas, Inc. has a twelve month low of $22.00 and a twelve month high of $58.58.

Arvinas (NASDAQ:ARVN – Get Rating) last posted its quarterly earnings results on Friday, May 5th. The company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.05). Arvinas had a negative net margin of 227.86% and a negative return on equity of 50.85%. The business had revenue of $32.50 million during the quarter, compared to analyst estimates of $27.74 million. During the same period in the previous year, the business posted ($1.20) EPS. The business’s revenue for the quarter was up 22.6% compared to the same quarter last year. On average, analysts anticipate that Arvinas, Inc. will post -6.7 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on ARVN. Credit Suisse Group dropped their target price on shares of Arvinas from $81.00 to $61.00 and set an “outperform” rating for the company in a report on Friday, February 24th. Citigroup increased their target price on shares of Arvinas from $72.00 to $77.00 in a report on Friday, March 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $90.00 price objective on shares of Arvinas in a report on Tuesday, January 31st. Morgan Stanley dropped their price objective on shares of Arvinas from $57.00 to $36.00 and set an “equal weight” rating for the company in a report on Monday, February 27th. Finally, Stifel Nicolaus dropped their price objective on shares of Arvinas from $75.00 to $72.00 in a report on Monday, May 8th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $67.33.

Insider Activity at Arvinas

In related news, CFO Sean A. Cassidy sold 1,745 shares of Arvinas stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $29.53, for a total value of $51,529.85. Following the completion of the sale, the chief financial officer now owns 183,618 shares of the company’s stock, valued at approximately $5,422,239.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Arvinas news, CEO John G. Houston sold 5,878 shares of Arvinas stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $29.53, for a total transaction of $173,577.34. Following the transaction, the chief executive officer now directly owns 917,427 shares of the company’s stock, valued at approximately $27,091,619.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sean A. Cassidy sold 1,745 shares of Arvinas stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $29.53, for a total transaction of $51,529.85. Following the transaction, the chief financial officer now directly owns 183,618 shares in the company, valued at $5,422,239.54. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,674 shares of company stock valued at $256,143. 2.78% of the stock is owned by company insiders.

About Arvinas

(Get Rating)

Arvinas, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.